GoPro Inc vs Revolution Medicines Inc. Common Stock — how do they compare? GoPro Inc trades at $1.19 (market cap $253.82M), while Revolution Medicines Inc. Common Stock trades at $188.5 (market cap $43.07B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 169.7× GoPro Inc's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| GPRO | RVMD | |
|---|---|---|
Market Cap | $253.82M | $43.07B |
Volume | 9,909,466 | 1,184,841 |
Sector | Technology | Health |
52-Week High | $2.35 | $221.15 |
52-Week Low | $0.58 | $47.50 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $312.60M | $39.77B |
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 10.61% today amid volatile trading following recent merger announcements. The stock shows bullish technical signals with oversold RSI conditions, while fundamentally the company faces significant challenges with negative profit margins and declining revenue. Recent developments include a proposed $285 million merger with Starman Optical and influencer Markiplier taking an 8.5% stake, driving substantial price volatility.
Investment outlook remains highly speculative with the merger offering potential upside from the $1.14 buyout price, but fundamental weakness and negative cash flow pose substantial risks. Analyst sentiment is mixed with only 21% recommending buy, while ongoing investigations into the merger's fairness add uncertainty to the transaction's completion.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →